Neovacs S.A.. (2/9/17). "Press Release: Neovacs Issued New Broad Patent in China for IFNalpha Kinoid". Paris.

	Region	China
	Organisation	Neovacs S.A. (Euronext Growth Paris: ALNEV)
	Group	Neovacs (Group)
	Organisation 2	LifeSci Advisors LLC
	Group	LifeSci (Group)
	Product	IFNalpha-Kinoid (IFNa-Kinoïd)
	Person	Sieler, Miguel (Neovacs 201310 CEO before Bayer France CEO at Bayer since 1975)
	Person 2	Maggos, Chris (BioConfidant / Cohesion Bureau 202303 Managing Director + Founder before LifeSci Advisors + Addex)

Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it has been granted a new patent from the Chinese Patent Office (SIPO), titled: "Method of treatment of a disease related to the overexpression of IFNa".

This new patent has been also filed in all major markets in the world, to cover the use of Neovacs’ IFNa Kinoid vaccine for all diseases characterized by an overexpression of the cytokine, Interferon alpha (IFNa), including Lupus, Dermatomyositis and Type 1 diabetes. This patent provides a strong protection until at least 2032.

Miguel Sieler, Chief Executive Officer of Neovacs, said: "Based on our innovative technology, Neovacs has a unique position globally in the field of autoimmune disease treatment. The issuance of this patent, and subsequent further expansion of our IP portfolio, represents further progress in the pursuit of our global development strategy for IFNa Kinoid. Moreover, this method of use patent will benefit our partnership discussions in China, where the prevalence of Lupus and Type 1 Diabetes is high1."

The patent significantly strengthens Neovacs’ IP portfolio, which now consists of 5 patent families worldwide, protecting the Company’s technology platform, product candidates and applications until at least 2032.

1 https://www.ncbi.nlm.nih.gov/pubmed/20477141
http://www.who.int/dg/speeches/2016/obesity-diabetes-disaster/en/

About Neovacs Technology

Neovacs targets pathologies associated with an overproduction of endogenous cytokines. This technology is based on active immunotherapy to generate an immune response through the administration of an immunogenic complex involving the target cytokine to a carrier protein. The intramuscular injection of this Kinoid induces an immune response and stimulates the production of polyclonal antibodies against the target cytokines. It is thus possible to block cytokine overproduction and its pharmacological effects. Several autoimmune and inflammatory diseases (e.g. systemic lupus erythematosus, dermatomyositis, Type 1 diabetes etc.) are characterized by a disorder of cytokines that are found to be produced in excess (ex: IFNa), promoting inflammation and dysregulation of the immune system.

About Neovacs

Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 1 53 10 93 14
cmasson@neovacs.com

LIFESCI ADVISORS – Investor Relations / Financial Communications
Chris Maggos
+41 79 367 6254 chris@lifesciadvisors.com

Record changed: 2023-06-05